EGFR and glioblastoma: Considering that IDH-wildtype diffuse astrocytic tumors without the histological features of glioblastoma but with TERT promoter mutations, EGFR amplification, or Chromosome 7 gain/Chromosome 10 loss (classified as glioblastomas in 2021 standard) may share similar histological features with the IDH-mutant Grade 2–3 astrocytoma, we also assessed the model’s ability in classifying these two categories (task 3).